Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors

Introduction. Sialadenitis is a frequent occurrence after radioactive iodine therapy (RAI). However, reports on its predictors and risk factors in the Eastern Mediterranean Region (EMRO) are scarce. Aim. This study aimed to identify risk factors for early sialadenitis in patients receiving RAI for d...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruba Riachy, Nisrine Ghazal, Mohamad B. Haidar, Ahmad Elamine, Mona P. Nasrallah
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2020/8649794
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568586745413632
author Ruba Riachy
Nisrine Ghazal
Mohamad B. Haidar
Ahmad Elamine
Mona P. Nasrallah
author_facet Ruba Riachy
Nisrine Ghazal
Mohamad B. Haidar
Ahmad Elamine
Mona P. Nasrallah
author_sort Ruba Riachy
collection DOAJ
description Introduction. Sialadenitis is a frequent occurrence after radioactive iodine therapy (RAI). However, reports on its predictors and risk factors in the Eastern Mediterranean Region (EMRO) are scarce. Aim. This study aimed to identify risk factors for early sialadenitis in patients receiving RAI for differentiated thyroid cancer (DTC) at the American University of Beirut Medical Center. It also aimed to determine the prevalence and characteristics of such patients receiving RAI at our institution. Methods. This was a retrospective study conducted at the American University of Beirut Medical Center. Medical charts were reviewed for all patients 18–79 years of age admitted to receive RAI for DTC between 01/01/2012 and 31/12/2015. Sialadenitis was deemed present if there were any records of neck swelling/pain, dry mouth, or difficulty swallowing within 48 hours of RAI administration. Characteristics between patients with sialadenitis and those without were compared to determine predictors. Results. There were 174 patients admitted to receive RAI, predominantly females (71.3%), with papillary thyroid cancer (93.1%). The majority had lymph node involvement (64.5%). Pretreatment thyroid stimulating hormone (TSH) was greater than 75 mIU/ml in most patients (72.6%). The prevalence of sialadenitis was 20.1% (95% CI (15–27)). Being non-Lebanese and having a positive whole-body scan were associated with sialadenitis and persisted after adjustments (OR = 2.34 and 3.99). Non-Lebanese patients had higher rates of lymph nodes involvement (p value 0.005) and were kept off levothyroxine for longer periods (p value 0.02). Conclusion. The prevalence of sialadenitis at our institution was similar to other reported studies from the world. However, risk factors allude to more iodine exposure in the neck with positive whole-body scan uptake, lymph node involvement, and prolonged period of hypothyroidism.
format Article
id doaj-art-99b0c6b179c148ea98be8efecf2a6dd2
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-99b0c6b179c148ea98be8efecf2a6dd22025-02-03T00:58:49ZengWileyInternational Journal of Endocrinology1687-83371687-83452020-01-01202010.1155/2020/86497948649794Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and PredictorsRuba Riachy0Nisrine Ghazal1Mohamad B. Haidar2Ahmad Elamine3Mona P. Nasrallah4Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut Medical Center, Beirut, LebanonDepartment of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut Medical Center, Beirut, LebanonDepartment of Radiology, Division of Nuclear Medicine, American University of Beirut Medical Center, Beirut, LebanonDepartment of Radiology, Division of Nuclear Medicine, American University of Beirut Medical Center, Beirut, LebanonDepartment of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut Medical Center, Beirut, LebanonIntroduction. Sialadenitis is a frequent occurrence after radioactive iodine therapy (RAI). However, reports on its predictors and risk factors in the Eastern Mediterranean Region (EMRO) are scarce. Aim. This study aimed to identify risk factors for early sialadenitis in patients receiving RAI for differentiated thyroid cancer (DTC) at the American University of Beirut Medical Center. It also aimed to determine the prevalence and characteristics of such patients receiving RAI at our institution. Methods. This was a retrospective study conducted at the American University of Beirut Medical Center. Medical charts were reviewed for all patients 18–79 years of age admitted to receive RAI for DTC between 01/01/2012 and 31/12/2015. Sialadenitis was deemed present if there were any records of neck swelling/pain, dry mouth, or difficulty swallowing within 48 hours of RAI administration. Characteristics between patients with sialadenitis and those without were compared to determine predictors. Results. There were 174 patients admitted to receive RAI, predominantly females (71.3%), with papillary thyroid cancer (93.1%). The majority had lymph node involvement (64.5%). Pretreatment thyroid stimulating hormone (TSH) was greater than 75 mIU/ml in most patients (72.6%). The prevalence of sialadenitis was 20.1% (95% CI (15–27)). Being non-Lebanese and having a positive whole-body scan were associated with sialadenitis and persisted after adjustments (OR = 2.34 and 3.99). Non-Lebanese patients had higher rates of lymph nodes involvement (p value 0.005) and were kept off levothyroxine for longer periods (p value 0.02). Conclusion. The prevalence of sialadenitis at our institution was similar to other reported studies from the world. However, risk factors allude to more iodine exposure in the neck with positive whole-body scan uptake, lymph node involvement, and prolonged period of hypothyroidism.http://dx.doi.org/10.1155/2020/8649794
spellingShingle Ruba Riachy
Nisrine Ghazal
Mohamad B. Haidar
Ahmad Elamine
Mona P. Nasrallah
Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
International Journal of Endocrinology
title Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
title_full Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
title_fullStr Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
title_full_unstemmed Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
title_short Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
title_sort early sialadenitis after radioactive iodine therapy for differentiated thyroid cancer prevalence and predictors
url http://dx.doi.org/10.1155/2020/8649794
work_keys_str_mv AT rubariachy earlysialadenitisafterradioactiveiodinetherapyfordifferentiatedthyroidcancerprevalenceandpredictors
AT nisrineghazal earlysialadenitisafterradioactiveiodinetherapyfordifferentiatedthyroidcancerprevalenceandpredictors
AT mohamadbhaidar earlysialadenitisafterradioactiveiodinetherapyfordifferentiatedthyroidcancerprevalenceandpredictors
AT ahmadelamine earlysialadenitisafterradioactiveiodinetherapyfordifferentiatedthyroidcancerprevalenceandpredictors
AT monapnasrallah earlysialadenitisafterradioactiveiodinetherapyfordifferentiatedthyroidcancerprevalenceandpredictors